How does Cosentyx work in the body?
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A), a signaling protein involved in inflammation. By binding to IL-17A, Cosentyx blocks IL-17A from interacting with its receptor, which reduces inflammatory pathways that drive conditions such as plaque psoriasis and certain forms of psoriatic arthritis and ankylosing spondylitis.[1]
Why does blocking IL-17A reduce psoriasis and arthritis symptoms?
IL-17A plays a central role in recruiting and activating immune cells and promoting inflammatory signaling in skin and joints. When IL-17A signaling is blocked, there is less downstream inflammation, which can lower symptoms such as skin plaque buildup, swelling, and pain associated with IL-17A–mediated disease activity.[1]
What cells or pathways are affected downstream?
By neutralizing IL-17A, secukinumab dampens IL-17A–dependent inflammatory signaling cascades. This reduces the immune-driven processes that contribute to inflammation in the skin and musculoskeletal system, including immune-cell activation and pro-inflammatory mediator production downstream of IL-17A.[1]
Is Cosentyx an IL-17 blocker, and how is that different from other biologics?
Yes. Cosentyx specifically targets IL-17A. Other biologics used in related diseases target different inflammatory drivers (for example, TNF or IL-12/23). The key difference is that Cosentyx’s mechanism is IL-17A neutralization rather than blockade of another immune pathway.[1]
What does this mean for safety or infection risk?
Because IL-17A is part of the body’s inflammatory and immune responses, blocking it can affect host defense mechanisms. In clinical practice, that means infections are monitored as a safety concern for IL-17–pathway inhibitors, consistent with how immune signaling is altered by IL-17A blockade.[1]
Sources
[1] https://www.drugs.com/cosentyx.html